Abstract
We investigated the effects of menatetrenone (vitamin K2) on pain and bone mass in osteoporosis. We prescribed 30mg of oral vitamin K2 per day to 12 female osteoporosis patients (age 64-77 years old) whose pain had not been relieved by 1.25 (OH)2D3 (vitamin D3), Elcatonin, NSAIDs, and physical therapy. Pain scores decreased in 11 of 12 patients following, 2 to 4 weeks treatment. Bone mass measured with computed X-ray densitometer 4 and 8 months after administration of vitamin K2 showed significant increase and improvement in pain score. The results indicate that vitamin K2 may be useful in the treatment of pain and bone loss in osteoporosis patients.
